Literature DB >> 9113345

Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1.

J Schmider1, D J Greenblatt, S M Fogelman, L L von Moltke, R I Shader.   

Abstract

Dextromethorphan (DMO), a cough suppressing synthetic analog of codeine, undergoes parallel O-demethylation to dextrorphan (DOP), and N-demethylation to 3-methoxymorphinan (MEM), in humans. 3-hydroxymorphinan, a didemethylated metabolite, is formed secondarily. O-demethylation activity is well established as an index reaction for CYP2D6. However, this pathway appears to be mediated by at least two different enzymes in vitro. N-demethylation activity has recently been proposed to reflect CYP3A3/4 activity. We investigated both pathways in vitro with microsomal preparations from three human livers to assess the value of DMO as a probe drug for CYP2D6 and CYP3A3/4, DMO O-demethylation displayed a biphasic pattern with a high-affinity site reflecting CYP2D6 activity (mean Ki for quinidine, 0.1 +/- 0.13 microM). Kinetic parameters for the two O-demethylation mediating enzymes predict an average relative intrinsic clearance (Vmax/K(m) ratio) of 96% of total O-demethylation mediated via the high-affinity enzyme. Thus, in vitro data confirms the usefulness of DMO O-demethylation as an index reaction to monitor CYP2D6 activity. The Eadie-Hofstee plot of DMO N-demethylation was consistent with single-enzyme Michaelis-Menten kinetics (Vmax varying from 3.3 to 6.8 nmol mg-1 min-1, K(m) from 231 to 322 microM). However, ketoconazole, a CYP3A3/4 inhibitor, reduced N-demethylation only by 60% and had a mean Ki an order of magnitude higher (0.37 microM) compared to other pure CYP3A3/4 mediated reactions. Troleandomycin, a mechanism based CYP3A3/4 inhibitor, inhibited MEM formation by an average maximum of 46%, with an IC50 varying from 1 to 2.6 microM. A polyclonal rat liver CYP3A1 antibody inhibited MEM formation only by approximately 50%. Diethyldithiocarbamate (DDC), a mechanism based CYP2E1 inhibitor, reduced MEM formation at concentrations up to 150 microM between 33 and 43%. Chemical inhibitors of CYP2d6 (quinidine), CYP1A1/2 (alpha-naphthoflavone), and CYP2C9 (sulfaphenazole), as well as a goat rat liver CYP2C11 polyclonal antibody (inhibitory against human CYP2C9 and CYP2C19), had minimal effect on MEM formation rate, thus excluding an involvement of any of these enzymes. DMO N-demethylation is only partly mediated by CYP3A3/4, and therefore is not a reliable index reaction for CYP3A3/4 activity either in vitro or probably in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9113345     DOI: 10.1002/(sici)1099-081x(199704)18:3<227::aid-bdd18>3.0.co;2-l

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  11 in total

1.  Pharmacokinetic profile of dextromethorphan hydrobromide in a syrup formulation in children and adolescents.

Authors:  Eric Guenin; Marianna Armogida; Dennis Riff
Journal:  Clin Drug Investig       Date:  2014-09       Impact factor: 2.859

2.  Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450.

Authors:  Julianna Oláh; Adrian J Mulholland; Jeremy N Harvey
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

3.  Effect of methamphetamine on the pharmacokinetics of dextromethorphan and midazolam in rats.

Authors:  M Dostalek; E Hadasova; M Hanesova; J Pistovcakova; A Sulcova; J Jurica; J Tomandl; I Linhart
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

4.  Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes.

Authors:  Jun Chen; Steven C Halls; Joshua F Alfaro; Zhaohui Zhou; Ming Hu
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

Review 5.  Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.

Authors:  Siamak Cyrus Khojasteh; Saileta Prabhu; Jane R Kenny; Jason S Halladay; Anthony Y H Lu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-19       Impact factor: 2.441

6.  The antitussive effect of dextromethorphan in relation to CYP2D6 activity.

Authors:  R Abdul Manap; C E Wright; A Gregory; A Rostami-Hodjegan; S T Meller; G R Kelm; M S Lennard; G T Tucker; A H Morice
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

7.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Authors:  A A Moghadamnia; A Rostami-Hodjegan; R Abdul-Manap; C E Wright; A H Morice; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

8.  Maintenance of liver functions in rat hepatocytes cultured as spheroids in a rotating wall vessel.

Authors:  Lanika A Brown; Linda M Arterburn; Ana P Miller; Nancy L Cowger; Sonya M Hartley; Annette Andrews; Paul M Silber; Albert P Li
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jan-Feb       Impact factor: 2.416

9.  Monoester-Diterpene Aconitum Alkaloid Metabolism in Human Liver Microsomes: Predominant Role of CYP3A4 and CYP3A5.

Authors:  Ling Ye; Xiao-Shan Yang; Lin-Lin Lu; Wei-Ying Chen; Shan Zeng; Tong-Meng Yan; Ling-Na Dong; Xiao-Juan Peng; Jian Shi; Zhong-Qiu Liu
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-23       Impact factor: 2.629

10.  Quantum mechanical modeling: a tool for the understanding of enzyme reactions.

Authors:  Gábor Náray-Szabó; Julianna Oláh; Balázs Krámos
Journal:  Biomolecules       Date:  2013-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.